ALC
Price
$74.31Alerts
Change
-$0.19 (-0.26%)
Updated
Nov 20 closing price
Capitalization
36.23B
100 days until earnings call
Intraday BUY SELL Signals
IQV
Price
$245.82Alerts
Change
-$4.73 (-1.89%)
Updated
Nov 20 closing price
Capitalization
44.74B
81 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ALC vs IQV

ALC vs IQV Comparison Chart in %
loading
loading
View a ticker or compare two or three
A.I.Advisor
Oct 20, 2026

Which Stock Would AI Choose? Alcon (ALC) vs. IQVIA Holdings (IQV) Stock Comparison

Key Takeaways

  • ALC (Alcon Inc.) is a Swiss-American eye-care and vision-products company, while IQV (IQVIA Holdings Inc.) is a global life-sciences data, analytics, and clinical-research services provider.
  • Both companies delivered second-quarter 2026 results that beat consensus and raised portions of their full-year guidance.
  • Alcon's share price has lagged in recent months despite solid fundamentals, while IQVIA has shown more consistent upward momentum.
  • IQVIA carries a "Strong Buy" analyst consensus and a positive artificial-intelligence-driven narrative, whereas Alcon holds a "Buy" consensus with a wider range of analyst views.
  • The two names differ sharply in risk profile: Alcon faces competitive and soft-volume pressures in eye surgery, while IQVIA carries elevated leverage and margin considerations.

Introduction

Investors evaluating healthcare exposure often weigh medical-device franchises against healthcare-services and data businesses, and the comparison between ALC and IQV captures that distinction clearly. Alcon is a leader in surgical ophthalmology and vision care, while IQVIA operates at the intersection of clinical research, healthcare data, and technology. This stock comparison is most relevant to traders and investors seeking to understand how two structurally different healthcare businesses perform on relative performance, market positioning, and sentiment. By examining recent earnings, growth drivers, and risk factors side by side, readers can better assess which profile aligns with their own market view.

ALC Overview and Recent Performance

Alcon Inc. (ALC) develops and sells surgical ophthalmology products—including intraocular lenses (IOLs), which are implanted during cataract surgery—as well as contact lenses and dry-eye treatments under brands such as Systane. In recent weeks, the stock has traded around the mid-to-high $60s range, reflecting a pullback from levels seen earlier in the year.

Fundamentally, the company has performed well. Second-quarter 2026 net sales rose to roughly $2.78 billion, up about 8% year over year, and adjusted earnings per share (EPS) of $0.84–$0.85 beat analyst estimates. Alcon also raised its full-year core EPS growth outlook to 12%–15% and trimmed its estimated tariff impact after an anticipated U.S. government refund. However, sentiment has been tempered by a one-time non-cash charge tied to discontinuing its PowerVision accommodating-IOL program, flat U.S. cataract procedure volumes, and competitive pressure in implantables. These factors help explain the stock's comparatively softer recent price action despite improving profitability.

IQV Overview and Recent Performance

IQVIA Holdings Inc. (IQV) provides clinical research services, healthcare data, and analytics to pharmaceutical and biotech clients, operating through its Research & Development Solutions and Commercial Solutions segments. In recent market activity, the stock has traded around the high $200s, supported by accelerating demand indicators.

Second-quarter 2026 adjusted EPS of $3.15 rose 12% year over year and beat consensus, on revenue of $4.36 billion, up 8.7%. The company reported record net new bookings in its R&D Solutions business and a book-to-bill ratio of 1.22X, signaling that new orders exceeded recognized revenue. Management has emphasized growing adoption of its artificial-intelligence offerings, including AI agents deployed across commercial and clinical workflows. Supporting sentiment, analysts have raised price targets in recent weeks, and the consensus rating stands at "Strong Buy." Offsetting factors include elevated leverage—net debt of roughly $14 billion, or about 3.6X adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization)—and higher restructuring costs.

Trending AI Robots

For traders seeking a systematic, data-driven edge, Tickeron's Trending AI Robots page curates a focused selection of its AI trading bots. Tickeron offers hundreds of AI Trading Bots that trade thousands of different tickers, but only the best performers most suited to current market conditions earn a place in this curated section. Each bot differs in trading style, strategy, timeframe, performance statistics, and the set of tickers it trades, allowing users to find approaches that match their own objectives and risk tolerance. The page highlights relevant metrics so visitors can evaluate and compare bots before making a decision. Explore the Trending AI Robots page to review the currently featured strategies.

Head-to-Head Comparison

At the business-model level, ALC is a product-driven medical-device and consumer-vision company, while IQV is a services- and data-driven healthcare enabler. Their growth engines differ accordingly: Alcon depends on surgical procedure volumes and product-innovation cycles such as its PanOptix Pro IOLs and Unity equipment platform, whereas IQVIA benefits from clinical-trial outsourcing, healthcare data demand, and AI adoption across life sciences.

On recent momentum, IQVIA has displayed more consistent strength, supported by record bookings and a strengthening AI narrative, while Alcon's share price has lagged even as earnings have beaten expectations. Risk profiles also contrast: Alcon faces competitive and reimbursement pressures in surgical glaucoma and flat U.S. cataract volumes, whereas IQVIA contends with a leveraged balance sheet and margin pressures from restructuring and business mix. In terms of sector exposure, Alcon sits squarely within eye care and medical devices, while IQVIA spans healthcare services and technology, giving each a distinct sensitivity to economic and regulatory cycles.

Tickeron AI Verdict

Based on observable factors, Tickeron's AI would likely favor IQV at present. The stock shows more consistent trend consistency, a clearer and strengthening catalyst in its artificial-intelligence and bookings momentum, and firmer analyst sentiment, as reflected in its "Strong Buy" consensus. Alcon's fundamentals remain solid, but its softer recent relative performance and competitive headwinds in implantables suggest less favorable positioning in the current market environment. This assessment is probabilistic rather than definitive: trend strength, catalysts, and stability can shift, and any comparative edge should be monitored as conditions evolve.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

VS
ALC vs. IQV commentary
Nov 22, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALC is a Hold and IQV is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ALC with price predictions
Nov 20, 2026

ALC's Stochastic Oscillator soaring into overbought zone

The Stochastic Oscillator for ALC moved into overbought territory on November 20, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for ALC moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 15 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 52%.

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALC as a result. In 47 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 52%.

The Moving Average Convergence Divergence Histogram (MACD) for ALC turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 30 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 57%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.

ALC broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

ALC moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ALC crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.

Following a +2.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALC advanced for three days, in 178 of 311 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.

The Aroon Indicator entered an Uptrend today. In 98 of 214 cases where ALC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 46%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. ALC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.678) is normal, around the industry mean (4.964). P/E Ratio (56.773) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (1.165) is also within normal values, averaging (4.143). Dividend Yield (0.014) settles around the average of (0.006) among similar stocks. P/S Ratio (2.996) is also within normal values, averaging (56.876).

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for IQV with price predictions
Nov 20, 2026

IQV in downward trend: price dove below 50-day moving average on November 13, 2026

IQV moved below its 50-day moving average on November 13, 2026 date and that indicates a change from an upward trend to a downward trend. In 20 of 27 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 74%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IQV as a result. In 50 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.

The Moving Average Convergence Divergence Histogram (MACD) for IQV turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 21 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 51%.

The 10-day moving average for IQV crossed bearishly below the 50-day moving average on November 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 62%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IQV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +5.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where IQV advanced for three days, in 186 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.

IQV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 43 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. IQV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.251) is normal, around the industry mean (67.298). P/E Ratio (33.477) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.985) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.693) is also within normal values, averaging (9.775).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IQV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.

FUNDAMENTALS RATINGS
ALC vs IQV: Fundamental Ratings
ALC
IQV
OUTLOOK RATING
1..100
7071
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
77
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8843
PRICE GROWTH RATING
1..100
4244
P/E GROWTH RATING
1..100
931
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ALC's Valuation (74) in the Hospital Or Nursing Management industry is in the same range as IQV (77) in the Servicestothe Health Industry industry. This means that ALC’s stock grew similarly to IQV’s over the last 12 months.

ALC's Profit vs Risk Rating (100) in the Hospital Or Nursing Management industry is in the same range as IQV (100) in the Servicestothe Health Industry industry. This means that ALC’s stock grew similarly to IQV’s over the last 12 months.

IQV's SMR Rating (43) in the Servicestothe Health Industry industry is somewhat better than the same rating for ALC (88) in the Hospital Or Nursing Management industry. This means that IQV’s stock grew somewhat faster than ALC’s over the last 12 months.

ALC's Price Growth Rating (42) in the Hospital Or Nursing Management industry is in the same range as IQV (44) in the Servicestothe Health Industry industry. This means that ALC’s stock grew similarly to IQV’s over the last 12 months.

ALC's P/E Growth Rating (9) in the Hospital Or Nursing Management industry is in the same range as IQV (31) in the Servicestothe Health Industry industry. This means that ALC’s stock grew similarly to IQV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALCIQV
RSI
ODDS (%)
Bearish Trend 3 days ago
52%
Bullish Trend 3 days ago
67%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
63%
Bullish Trend 3 days ago
65%
Momentum
ODDS (%)
Bearish Trend 3 days ago
52%
Bearish Trend 3 days ago
65%
MACD
ODDS (%)
Bearish Trend 3 days ago
57%
Bearish Trend 3 days ago
51%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
59%
Bearish Trend 3 days ago
65%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
57%
Bearish Trend 3 days ago
71%
Advances
ODDS (%)
Bullish Trend 5 days ago
57%
Bullish Trend 14 days ago
62%
Declines
ODDS (%)
Bearish Trend 3 days ago
55%
Bearish Trend 3 days ago
64%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
57%
Bullish Trend 3 days ago
55%
Aroon
ODDS (%)
Bullish Trend 3 days ago
46%
N/A
COMPARISON
Comparison
Nov 22, 2026
Stock price -- (ALC: $74.31 vs. IQV: $245.82)
Brand notoriety: ALC: Not notable vs. IQV: Notable
ALC represents the Pharmaceuticals: Other, while IQV is part of the Medical Specialties industry
Current volume relative to the 65-day Moving Average: ALC: 153% vs. IQV: 84%
Market capitalization -- ALC: $36.23B vs. IQV: $44.74B
ALC [@Pharmaceuticals: Other] is valued at $36.23B. IQV’s [@Medical Specialties] market capitalization is $44.74B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $126 to $159.96B. The market cap for tickers in the [@Medical Specialties] industry ranges from $27 to $4.39T. The average market capitalization across the [@Pharmaceuticals: Other] industry is $9.78B. The average market capitalization across the [@Medical Specialties] industry is $20.94B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALC’s FA Score shows that 1 FA rating(s) are green while IQV’s FA Score has 1 green FA rating(s).

  • ALC’s FA Score: 1 green, 4 red.
  • IQV’s FA Score: 1 green, 4 red.
According to our system of comparison, IQV is a better buy in the long-term than ALC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALC’s TA Score shows that 4 TA indicator(s) are bullish while IQV’s TA Score has 4 bullish TA indicator(s).

  • ALC’s TA Score: 4 bullish, 6 bearish.
  • IQV’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, IQV is a better buy in the short-term than ALC.

Price Growth

ALC (@Pharmaceuticals: Other) experienced а +0.26% price change this week, while IQV (@Medical Specialties) price change was -7.28% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -7.82%. For the same industry, the average monthly price growth was -5.08%, and the average quarterly price growth was +4.34%.

The average weekly price growth across all stocks in the @Medical Specialties industry was -9.90%. For the same industry, the average monthly price growth was -17.15%, and the average quarterly price growth was +16.33%.

Reported Earning Dates

ALC is expected to report earnings on Mar 02, 2027.

IQV is expected to report earnings on Feb 11, 2027.

Industries' Descriptions

@Pharmaceuticals: Other (-7.82% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

@Medical Specialties (-9.90% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NCDL11.25-0.07
-0.62%
Nuveen Churchill Direct Lending Corp
GELS0.28N/A
-0.93%
Gelteq Ltd
RRR46.09-0.56
-1.20%
Red Rock Resorts
ICLR186.71-3.65
-1.92%
ICON plc
GLND1.65-0.24
-12.70%
Greenland Energy Company